



Rescriptor[®] (delavirdine mesylate) – Product discontinuation

- On May 11, 2017, the [FDA announced](#) the discontinuation of ViiV Healthcare's [Rescriptor \(delavirdine mesylate\)](#) 100 mg and 200 mg tablets due to business reasons.
 - The discontinuation is not due to product quality, safety, or efficacy concerns.
 - The anticipated final date of availability for the 100 mg tablets is October 2018.
 - The anticipated final date of availability for the 200 mg tablets is February 2020.
- Rescriptor is indicated for the treatment of human immunodeficiency virus type 1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.
 - Resistant virus emerges rapidly when Rescriptor is administered as monotherapy. Therefore, Rescriptor should always be administered in combination with other antiretroviral agents.
- Other non-nucleoside reverse transcriptase inhibitors that share similar indications as Rescriptor include [Edurant[®] \(rilpivirine\)](#), [Intelence[®] \(etravirine\)](#), [nevirapine](#), [nevirapine extended-release](#), and [Sustiva[®] \(efavirenz\)](#).

Refer to the individual drug labels for specific indication and dosing information.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.